New Report Shows Optical Molecular Imaging to Become = Key Tool in Personalized Medicine

Nikon=20 Releases New AF-S NIKKOR 24mm f/1.4G ED=20 Lens

AAXA=20 Technologies Unleashes Industry's First = Laser=20 Pico = Projector

Olympus=20 Unleashes World's First 30x Optical Zoom = Compact=20 Digital = Camera

Konica=20 Minolta and Oce Terminate Business = Alliance Deal=20 on Office Printing=20 Systems

Vishay=20 Unveils Two Versions of Surface-Mount = White=20 = LEDs

DALSA=20 Offers Customized HV CMOS Fabrication = and HV=20 ASIC Design=20 Service

Hiden=20 Analytical Introduces Transient MS = system for=20 Gas = Analysis

New=20 Digital Microscopes from Leica=20 = Microsystems

SEMATECH=20 Launches Global Consortium to Develop = Critical=20 EUV Metrology=20 Tools

HP=20 Introduces Digital Press Solutions for = Enhanced=20 Photo Printing Quality and Color=20 = Consistency

Xerox=20 and Fuji Partnership Brings Managed = Print=20 Services to=20 = Classroom

Epson=20 Releases New Projectors for Education=20 Sector

New=20 Olympus PEN E-PL1 Camera Features Bigger = Model's=20 Technology in Small=20 Body

MODIS=20 Instrument Captures Storm Magda in = Northern=20 = Australia

Inovateus=20 to Become Scheuten Solar's North = American=20 Channel=20 = Partner

Tab=20 options

In vivo optical molecular imaging (OMI) is = poised to=20 move into clinical use as one of the key tools = in=20 personalized medicine, complementing more = established=20 imaging tools such as CT and MRI. Growth of = equipment=20 sales is on track to reach $400 million in 2014 = and=20 nearly $1 billion by the end of the decade. =

However, this strong growth hinges on = partnerships=20 with key medical equipment vendors, the outcomes = of=20 clinical trials assessing imaging agents, = regulatory=20 approvals, patent litigation, and decisions = about=20 insurance reimbursement. These are some of the = findings=20 of a new market report from Strategies = Unlimited.

Optical molecular imaging is an attractive = and=20 cost-effective tool for examining and monitoring = disease=20 states and to determine a drug=92s effectiveness = in living=20 tissue. Highly portable, fast, and less = expensive than=20 conventional imaging technologies, it has the = potential=20 to bring sophisticated diagnostics right to the = doctor=92s=20 office. When coupled with more traditional = imaging tools=20 such as CT and MRI, optical imaging adds an=20 unprecedented degree of quantification and = specificity=20 to the healthcare decision-making process.

The market will likely expand in two = complementary=20 directions: research systems and clinical = systems. The=20 research market will continue at a steady pace = as OMI=20 approaches become more widely used for drug = discovery=20 and preclinical studies. Recent advances in = imaging=20 agents will power the transition of optical = techniques=20 from the lab to clinical settings. Cameras and = optical=20 filters will also be integral components of the = clinical=20 devices.

Large imaging firms, such as GE Healthcare, = Siemens,=20 and Philips, are beginning to pursue optical = molecular=20 imaging, while over 12 companies are already = marketing=20 OMI systems.

Source: http://www.strategies-u.com/

Published Date: = 21/1/2010=20

New Report Shows Optical Molecular Imaging = to Become=20 Key Tool in Personalized Medicine